BeiGene appoints Changzhen Wu as head of manufacturing operations
He will be responsible for all aspects of construction of the Suzhou manufacturing facility, and will lead manufacturing operations for BeiGene’s small-molecules, including production, engineering, quality operations, supply chain and logistics.
BeiGene has hired highly regarded industry veteran Changzhen Wu as Head of Manufacturing Operations. Mr Wu has a proven track record and the distinctive capabilities in overseeing construction of biopharmaceutical plants and leading manufacturing operations. He will be responsible for all aspects of construction of the Suzhou manufacturing facility. In addition, Mr Wu will lead manufacturing operations for BeiGene’s small-molecules, including production, engineering, quality operations, supply chain, and logistics. He will report to CEO, John V. Oyler and Research Head of Chemistry, Zhiwei Wang.
“Changzhen is an extremely valuable addition to our team” said John V. Oyler, CEO of BeiGene. “He is very well respected and has many established relationships in the industry. His unparalleled knowledge in the production of small-molecule drugs, and overseeing plant construction to managing day to day operations, is a strong complement to our existing team and critical to our future strategies.”
Mr Wu brings over four decades of combined experience in engineering, manufacturing, operations, and process design and development. Prior to joining BeiGene, Mr Wu was at Pharmacia where he was instrumental in leading the construction of its oncology manufacturing plant in China. Previously, Mr Wu was the Head Plant Manager at Pfizer Pharmaceutical (WuXi) for over 10 years. Prior to Pfizer, he was the Chief Engineer at Sino-Sweden Pharmaceutical for 15 years. Mr Wu began his career at China North-West API Pharmaceutical, where he spent over 16 years as a process engineer. He graduated from Shanghai Medical University with a Bachelor’s degree in Pharmacology.
“I am thrilled to be joining BeiGene to help scale its operations to address both current needs, as well as future opportunities,” said Mr Wu. “We plan to not only grow our manufacturing operations, but also promote and work in conjunction with other divisions of BeiGene to achieve our company goals.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance